LEGN vs. ABBV
LEGN (Legend Biotech Corporation) and ABBV (AbbVie Inc.) are both stocks. Both are in the Healthcare sector — LEGN in Biotechnology, ABBV in Drug Manufacturers - General. Over the past 5 years, LEGN returned -7.67%/yr vs 20.75%/yr for ABBV. At a 0.17 correlation, their price movements are largely independent.
Performance
LEGN vs. ABBV - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, LEGN achieves a 24.56% return, which is significantly higher than ABBV's 10.36% return.
LEGN
- 1D
- -1.10%
- 1M
- -24.51%
- 6M
- 14.75%
- YTD
- 24.56%
- 1Y
- -30.49%
- 3Y*
- -27.72%
- 5Y*
- -7.67%
- 10Y*
- —
ABBV
- 1D
- -0.73%
- 1M
- 8.94%
- 6M
- 14.57%
- YTD
- 10.36%
- 1Y
- 33.11%
- 3Y*
- 26.78%
- 5Y*
- 20.75%
- 10Y*
- 19.05%
LEGN vs. ABBV - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
LEGN Legend Biotech Corporation | 24.56% | -33.19% | -45.92% | 20.53% | 7.10% | 65.52% | -23.89% |
ABBV AbbVie Inc. | 10.36% | 33.08% | 18.86% | -0.23% | 24.01% | 32.43% | 18.16% |
Correlation
The correlation between LEGN and ABBV is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.19 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.19 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.17 |
Correlation (All Time) Calculated using the full available price history since Jun 5, 2020 | 0.17 |
Fundamentals
LEGN:
$5.01B
ABBV:
$438.31B
LEGN:
-$1.63
ABBV:
$2.05
LEGN:
3.65
ABBV:
7.00
LEGN:
2.59
ABBV:
16.00
LEGN:
$1.14B
ABBV:
$62.82B
LEGN:
$611.63M
ABBV:
$46.15B
LEGN:
-$186.04M
ABBV:
$17.96B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
LEGN vs. ABBV — Risk / Return Rank
LEGN
ABBV
LEGN vs. ABBV - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Legend Biotech Corporation (LEGN) and AbbVie Inc. (ABBV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| LEGN | ABBV | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.68 | ||
| Sortino ratioReturn per unit of downside risk | -2.27 | ||
| Omega ratioGain probability vs. loss probability | 0.95 | 1.23 | -0.28 |
| Calmar ratioReturn relative to maximum drawdown | -0.51 | 1.82 | -2.33 |
| Martin ratioReturn relative to average drawdown | -0.78 | 4.04 | -4.83 |
Loading charts...
Drawdowns
LEGN vs. ABBV - Drawdown Comparison
The maximum LEGN drawdown since its inception was -78.24%, which is greater than ABBV's maximum drawdown of -45.09%. Use the drawdown chart below to compare losses from any high point for LEGN and ABBV.
Loading charts...
Drawdown Indicators
| LEGN | ABBV | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -78.24% | -45.09% | -33.15% |
Max Drawdown (1Y)Largest decline over 1 year | -62.43% | -17.32% | -45.11% |
Max Drawdown (3Y)Largest decline over 3 years | -78.24% | -20.74% | -57.50% |
Max Drawdown (5Y)Largest decline over 5 years | -78.24% | -21.92% | -56.32% |
Max Drawdown (10Y)Largest decline over 10 years | — | -45.09% | — |
Current DrawdownCurrent decline from peak | -64.60% | -4.98% | -59.62% |
Average DrawdownAverage peak-to-trough decline | -31.78% | -10.67% | -21.11% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 40.62% | 7.79% | +32.83% |
Volatility
LEGN vs. ABBV - Volatility Comparison
Legend Biotech Corporation (LEGN) has a higher volatility of 22.64% compared to AbbVie Inc. (ABBV) at 10.48%. This indicates that LEGN's price experiences larger fluctuations and is considered to be riskier than ABBV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| LEGN | ABBV | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 22.64% | 10.48% | +12.16% |
Volatility (6M)Calculated over the trailing 6-month period | 60.26% | 19.44% | +40.82% |
Volatility (1Y)Calculated over the trailing 1-year period | 70.14% | 25.92% | +44.22% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 56.80% | 23.32% | +33.48% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 55.99% | 25.87% | +30.12% |
Dividends
LEGN vs. ABBV - Dividend Comparison
LEGN has not paid dividends to shareholders, while ABBV's dividend yield for the trailing twelve months is around 2.72%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ABBV AbbVie Inc. | 2.72% | 2.87% | 3.49% | 3.82% | 3.49% | 3.84% | 4.41% | 4.83% | 3.89% | 2.65% | 3.64% | 3.41% |
LEGN Legend Biotech Corporation | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
LEGN vs. ABBV - Financials Comparison
This section allows you to compare key financial metrics between Legend Biotech Corporation and AbbVie Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
LEGN vs. ABBV - Profitability Comparison
LEGN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Legend Biotech Corporation reported a gross profit of 113.94M and revenue of 306.01M. Therefore, the gross margin over that period was 37.2%.
ABBV - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, AbbVie Inc. reported a gross profit of 12.53B and revenue of 15.00B. Therefore, the gross margin over that period was 83.5%.
LEGN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Legend Biotech Corporation reported an operating income of -47.04M and revenue of 306.01M, resulting in an operating margin of -15.4%.
ABBV - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, AbbVie Inc. reported an operating income of 4.73B and revenue of 15.00B, resulting in an operating margin of 31.6%.
LEGN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Legend Biotech Corporation reported a net income of -54.46M and revenue of 306.01M, resulting in a net margin of -17.8%.
ABBV - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, AbbVie Inc. reported a net income of 699.00M and revenue of 15.00B, resulting in a net margin of 4.7%.
Frequently Asked Questions
LEGN and ABBV have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
LEGN has higher volatility (22.64%) compared to ABBV (10.48%). In terms of maximum drawdown, LEGN dropped -78.24% vs ABBV's -45.09%.
ABBV currently has the higher Sharpe Ratio (1.22 vs -0.46), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for LEGN and ABBV
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer